EG110A

DRUG2 trials

Sponsors

Cyllene Therapeutics, EG 427

Conditions

Neurogenic Detrusor OveractivitySpinal Cord InjuriesSpinal Cord InjuryUrinary Bladder, Overactive

Phase 1

Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization

RecruitingNCT06596291

Cyllene TherapeuticsNeurogenic Detrusor Overactivity, Spinal Cord Injuries

Start: 2025-01-08End: 2027-06-01Target: 16Updated: 2026-09-03

Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy

Not yet recruitingNCT07227285

EG 427Spinal Cord Injury, Urinary Bladder, Overactive

Start: 2026-04-30End: 2031-04-30Target: 16Updated: 2025-11-12